Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX010 psilocybin for prolonged grief disorder
2024-518218-24-00Phase 2Authorised
- Sponsor
- Linköping University
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PEX010 in complicated grief disorder (PGD) (2 arms), sponsored by Linköping University. Primary endpoint: Primary PG13-R score. Planned start Feb 2025; status: authorised.
02
Drugs
PEX010
03
Conditions
complicated grief disorder (PGD)
Beyond the preview
Go deeper on 2024-518218-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518218-24-00.